Enzymotec Ltd.'s ability to collect its outstanding accounts receivable from its corporate clients, has improved in the fourth quarter 2016 to a ratio of 4.75, above the company average. This is a clear sign of healthy business climate in the Biotechnology & Pharmaceuticals industry and improving liquidity at their respective customers, during the fourth quarter 2016. Average receivable collection period, for the Enzymotec Ltd. in Dec 31 2016 quarter, has decreased to 77 days, compared to 82 days, in the 0 quarter.

If we take a look into Healthcare sector 290 other companies have achieved higher receivables turnover ratio. While total ranking has deteriorated relative to the period ending Dec 31 2016 from 0 to 2537.

What is Receivable Turnover Ratio?
What is Enzymotec Ltd. Selling?

What is Receivable Turnover Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Accounts Receivables Turnover▼

None ▼

Accounts Receivables Turnover▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

ENZY Receivables Turnover Ratio	(Dec 31 2016) IV. Quarter	0 III. Quarter	0 II. Quarter	0 I. Quarter	(Dec 31 2015) IV. Quarter
Y / Y Receivable Change	-32.88 %	-32.88 %	-32.88 %	-32.88 %	6004.49 %
Y / Y Revenue Change	-5.35 %	-	-	-	6.98 %
Receivable Turnover Ratio (TTM)	4.75	4.47	4.03	3.67	3.37
ENZY's Total Ranking	# 2537	# 0	# 3065	# 0	# 0
Accounts Receivable average collection period days	77	82	91	99	108
Seq. Receivable Change	0 %	0 %	0 %	-32.88 %	0 %
Seq. Revenue Change	-	-	-	-	-

Receivable Turnover Company Ranking
Within:	No.
Biotechnology & Pharmaceuticals Industry	# 17
Healthcare Sector	# 291
Overall Market	# 2537

Receivable Turnover Ratio Statistics
High	Average	Low
0.34	0.33	0.32
(Dec 31 2015)		(Dec 31 2016)

ENZY Company Profile • Back to ENZY Efficiency Comparisons • Compare ENZY Receivables Turnover Ratio to its Competitors

Financial Statements
Enzymotec Ltd.'s Accounts Receivable	$ 10 Millions	Visit ENZY's Balance sheet
Enzymotec Ltd.'s Sales TTM	$ 48 Millions	Visit ENZY's Income Statement
Sources of ENZY's Revenues		Visit ENZY's Sales by Geography

Other Accounts Receivable Turnover Ratios
Biotechnology & Pharmaceuticals Industry Accounts Receivable Turnover Trends and Statistics
Healthcare Sector Accounts Receivable Turnover Statistics
Accounts Receivables Turnover Trends for overall market
ENZY's Receivable Turnover Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Accounts Receivables Turnover
Lowest Ranking Accounts Receivables Turnover

You may also want to know
ENZY's Growth Rates	ENZY's Roa	ENZY's Inventory Turnover Ratio	ENZY's Dividend Comparisons
ENZY's Profitability Ratios	ENZY's Roi	ENZY's Asset Turnover Ratio	ENZY's Dividend Growth
ENZY's Valuation Ratios	ENZY's Roe	ENZY's Financial Strength Ratios	ENZY's Dividend Payout Ratio

Companies with similar Receivables Turnover Ratio for the quarter ending Dec 31 2016, within Healthcare Sector	Receivable Turnover Ratio	Revenues for 12 Months ending Dec 31 2016	Receivable at quarter ending Dec 31 2016
Arena Pharmaceuticals Inc	12.99	$ 92.163 Millions	$ 7.097 Millions
Vivosim Labs Inc	12.93	$ 3.966 Millions	$ 0.307 Millions
Irhythm Holdings Inc	12.92	$ 64.072 Millions	$ 4.960 Millions
Gi Dynamics Inc	12.90	$ 0.545 Millions	$ 0.042 Millions
Armata Pharmaceuticals Inc	12.84	$ 0.260 Millions	$ 0.020 Millions
Integrated Biopharma Inc	12.68	$ 47.409 Millions	$ 3.739 Millions
Labcorp Holdings Inc	12.62	$ 16,783.800 Millions	$ 1,329.550 Millions
Lifemd Inc	12.55	$ 5.239 Millions	$ 0.418 Millions
Miragen Therapeutics Inc	12.43	$ 3.090 Millions	$ 0.249 Millions
Oncomed Pharmaceuticals Inc	12.43	$ 25.153 Millions	$ 2.023 Millions
Pro dex Inc	12.41	$ 20.633 Millions	$ 1.662 Millions
Lifeloc Technologies Inc	12.39	$ 8.381 Millions	$ 0.676 Millions
Icagen, Inc.	12.35	$ 11.995 Millions	$ 0.971 Millions
Vtv Therapeutics Inc	12.31	$ 0.634 Millions	$ 0.052 Millions
T2 Biosystems Inc	12.05	$ 4.080 Millions	$ 0.339 Millions
Veracyte Inc	12.01	$ 65.085 Millions	$ 5.421 Millions
Acceleron Pharma inc	11.92	$ 27.770 Millions	$ 2.329 Millions
National Healthcare Corp	11.65	$ 926.638 Millions	$ 79.536 Millions
Vivus Inc	11.65	$ 124.258 Millions	$ 10.668 Millions
Lexaria Bioscience Corp	11.56	$ 0.926 Millions	$ 0.080 Millions
Nuo Therapeutics Inc	11.50	$ 11.511 Millions	$ 1.001 Millions
Tactile Systems Technology Inc	11.41	$ 84.542 Millions	$ 7.407 Millions
Portola Pharmaceuticals inc	11.36	$ 35.504 Millions	$ 3.125 Millions
Tearlab Corp	11.24	$ 28.014 Millions	$ 2.492 Millions
Surmodics Inc	11.10	$ 72.586 Millions	$ 6.541 Millions
Acorda Therapeutics Inc	11.04	$ 519.601 Millions	$ 47.081 Millions
Caredx Inc	11.03	$ 40.631 Millions	$ 3.684 Millions
Intercept Pharmaceuticals inc	10.94	$ 24.951 Millions	$ 2.282 Millions
Kushco Holdings Inc	10.82	$ 2.472 Millions	$ 0.229 Millions
Five Prime Therapeutics Inc	10.75	$ 30.691 Millions	$ 2.856 Millions

Date modified: 2026-09-02T18:56:07+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.